Will Selecta Biosciences be the Next Top Platform Biotech?

Automatic TRANSCRIPT

The first company. I wanted to touch on is news from july lilly and they're huge company. Say like a large mega cap at one hundred and eighty three billion dollars and what they recently presented was the full data set from their molecule demand in alzheimer's disease. And this is a phase two trial looking at this antibody that targets a specific epoch on the amyloid beta approaching and this episode is only visible in established plaques. Now i don't want to belabor the point about the amyloid hypothesis which i've done in previous videos. Suffice to say that a number of different molecules have been attempted in this indication in specifically the mechanism of reducing amyloid plaques. And they've all failed and what we're seeing here is that in this multi center randomized double blind placebo controlled trial. That donna had a significant is what they're showing here in the air score but not a very profound impact on cognition and so they looked at this primary outcome the air score and this is a combination of the as well as the ads. Ads and so eight ask cogs general measure of cognition whereas the ads. I is a measure of activities of daily living. So they did a combined score with that and demanded mobs improvement led to a p value of point zero four so technically significant. But i'm not sure that if they replicated the stayed in a face. Three trout necessarily be positive. It is an interesting thing because when you look at the actual aid. S cog thirteen score. We don't see any significant change. It is better in indiana but not by a significant margin and then the mse score is basically no difference between the two so this is another data point to suggest that perhaps the amyloid beta hypothesis isn't one that these companies should be looking at and the last thing i wanted to show here. Is that the one thing that they do. See a significant change in the amount of amyloid in the brain and so the pet scan here to show that the dynamic treated group has a significant reduction in the amount of amyloid plaque in the brain compared to placebo. So the drug is able to reduce the emily beta plaques. But it's not able to improve cognition really as much as you would expect given the effect is there so i wanted to bring this up because there is an upcoming. Pdf date for biogen's advocating mob and this is going to be a huge movie for the stock and it was originally supposed to be in march but it was delayed until june seventh of this year. So keep your eyes on that. I don't know if i'm going to make any position on it. I think that the fda should not approve it given the results from the advisory committee but given that the so many is on this pdf. I feel like there's a chance at the fda could overlook that and end up approving drug. So it's definitely jairo word. Play and i would treat it as such and proceed likewise so that is eli lilly. I wanna quickly move on to another company in the alzheimer's face called novus and i touched on them in my previous video and what we heard in the last week was that they announced positive face to data and this is interim data showing the nbs for one or another name for the molecule is positive in improved speed and coordination in parkinson's patients. And this is a twenty five day treatment. Nine patients were in the treatment group and five or in the placebo and on the announcement of this data. I think the stock was trading around one hundred fifty maybe two hundred million dollars market valuation and went up to around two fifty three hundred before settling around two hundred and fifty million dollar market cap so big move up in the stock and i'll tell you the data. The ceo explained that the study was power to investigate a difference of twenty to twenty five percent in biomarker levels not to demonstrate efficacy making this data that much more significant so to provide some context. And why i think this is interesting. Is that i in my previous video. Didn't really seem to bullish on a novus and the reason for this is that it reminds me very closely other types of amyloid beta drugs because this drug reduces app the precursor protein to amyloid beta. So my rationale is that if they're targeting the same emily data pathway. Given that there's been so many molecules that have failed previously targeting that pathway. I don't expect that this one is going to be any different now. Having said that. I decided to take a position because we've seen over and over again. That companies have been able to spin face to data in a positive way that leads to these big increases in the sock even though in phase three there's an eventual failure so i decided to take a position in stock and i have been rewarded handsomely so far and i'm going to hold on to see the rest of the phase two data so to get the actual data here in one test that measures the speed of execution. The results were statistically significant. P equals zero point zero four showing that while parkinson's disease patients are slow in coding. Boxes met with an s four. Zero one improves their performance. In these same patients other test that measures coordination showed an improvement in their movements and was almost statistically significant peak will s- appoint zero seven. Then they say in all end. Es up tests performed the placebo group either stayed the same or performed worse than at baseline instead the a b s four zero one group either stayed the same perform better than at baseline and as we know. Md s up drs is a specific tasks that measures severity and progression of the disease.

Coming up next